Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
Loading...
Issue Date
2014-07
Authors
Felton, T W
Roberts, Jason A
Lodise, Thomas P
Van Guilder, M
Boselli, E
Neely, Michael N
Hope, William W
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in critically ill patients. Considerable pharmacokinetic (PK) variability is observed in critically ill patients. By estimating an individual's PK, dosage optimization Bayesian estimation techniques can be used to calculate the appropriate piperacillin regimen to achieve desired drug exposure targets. The aim of this study was to establish a population PK model for piperacillin in critically ill patients and then analyze the performance of the model in the dose optimization software program BestDose. Linear, with estimated creatinine clearance and weight as covariates, Michaelis-Menten (MM) and parallel linear/MM structural models were fitted to the data from 146 critically ill patients with nosocomial infection. Piperacillin concentrations measured in the first dosing interval, from each of 8 additional individuals, combined with the population model were embedded into the dose optimization software. The impact of the number of observations was assessed. Precision was assessed by (i) the predicted piperacillin dosage and by (ii) linear regression of the observed-versus-predicted piperacillin concentrations from the second 24 h of treatment. We found that a linear clearance model with creatinine clearance and weight as covariates for drug clearance and volume of distribution, respectively, best described the observed data. When there were at least two observed piperacillin concentrations, the dose optimization software predicted a mean piperacillin dosage of 4.02 g in the 8 patients administered piperacillin doses of 4.00 g. Linear regression of the observed-versus-predicted piperacillin concentrations for 8 individuals after 24 h of piperacillin dosing demonstrated an r(2) of >0.89. In conclusion, for most critically ill patients, individualized piperacillin regimens delivering a target serum piperacillin concentration is achievable. Further validation of the dosage optimization software in a clinical trial is required.
Citation
Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely MN, Hope WW. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother. 2014 Jul;58(7):4094-102. doi: 10.1128/AAC.02664-14. Epub 2014 May 5. PMID: 24798288; PMCID: PMC4068511.
ACPHS Research Commons URI
Description
Grants
R01 HD070886/HD/NICHD NIH HHS/United States , CS/08/08/10/Department of Health/United Kingdom , G1000417/Medical Research Council/United Kingdom , G1000417/94909/MRC_/Medical Research Council/United Kingdom , R01 GM068968/GM/NIGMS NIH HHS/United States